AR125191A1 - Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso - Google Patents
Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de usoInfo
- Publication number
- AR125191A1 AR125191A1 ARP220100668A ARP220100668A AR125191A1 AR 125191 A1 AR125191 A1 AR 125191A1 AR P220100668 A ARP220100668 A AR P220100668A AR P220100668 A ARP220100668 A AR P220100668A AR 125191 A1 AR125191 A1 AR 125191A1
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- seq
- acid sequence
- deaminase
- fusion protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04001—Cytosine deaminase (3.5.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se proporcionan composiciones y métodos que comprenden polipéptidos de desaminasa para la edición dirigida de ácidos nucleicos. Las composiciones comprenden polipéptidos de desaminasa. También se proporcionan proteínas de fusión que comprenden un polipéptido de unión a ADN y una desaminasa de la invención. Las proteínas de fusión incluyen nucleasas guiadas por ARN fusionadas con desaminasas, opcionalmente en complejo con ARN guía. Las composiciones también incluyen moléculas de ácido nucleico que codifican las desaminasas o las proteínas de fusión. También se proporcionan vectores y células huésped que comprenden las moléculas de ácido nucleico que codifican las desaminasas o las proteínas de fusión. Reivindicación 1: Un polipéptido que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en: a) una secuencia de aminoácidos que tiene al menos un 90% de identidad de secuencia con cualquiera de las SEQ ID Nº 2 y 7 - 12; y b) una secuencia de aminoácidos que tiene al menos un 95% de identidad de secuencia con SEQ ID Nº 4 ó 6; en donde dicho polipéptido tiene actividad de desaminasa. Reivindicación 5: La molécula de ácido nucleico de acuerdo con la reivindicación 3, en donde la desaminasa está codificada por una secuencia de nucleótidos que tiene una identidad de secuencia del 100% con cualquiera de las SEQ ID Nº 109, 111 y 113 - 119. Reivindicación 13: El método de acuerdo con la reivindicación 11 ó 12, que comprende además purificar dicha desaminasa. Reivindicación 14: Una proteína de fusión que comprende un polipéptido de unión a ADN y una desaminasa que tiene una secuencia de aminoácidos seleccionada del grupo que consiste en: a) una secuencia de aminoácidos que tiene al menos un 90% de identidad de secuencia con cualquiera de las SEQ ID Nº 2 y 7 - 12; y b) una secuencia de aminoácidos que tiene al menos un 95% de identidad de secuencia con SEQ ID Nº 4 ó 6. Reivindicación 27: La proteína de fusión de acuerdo con la reivindicación 19, en donde la RGN tiene una secuencia de aminoácidos de cualquiera de las SEQ ID Nº 74, 82, 87, 106 y 107. Reivindicación 30: La proteína de fusión de acuerdo con cualquiera de las reivindicaciones 14 - 29, en donde la proteína de fusión comprende además al menos una señal de localización nuclear (NLS). Reivindicación 33: La proteína de fusión de acuerdo con la reivindicación 14, en donde dicha proteína de fusión tiene una secuencia de aminoácidos de cualquiera de las SEQ ID Nº 67, 68, 146 y 147.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163164273P | 2021-03-22 | 2021-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125191A1 true AR125191A1 (es) | 2023-06-21 |
Family
ID=81307870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100668A AR125191A1 (es) | 2021-03-22 | 2022-03-22 | Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4314266A1 (es) |
| JP (1) | JP2024511131A (es) |
| CN (1) | CN117295817A (es) |
| AR (1) | AR125191A1 (es) |
| AU (1) | AU2022242754A1 (es) |
| CA (1) | CA3173950A1 (es) |
| TW (1) | TW202300649A (es) |
| WO (1) | WO2022204093A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024042489A1 (en) | 2022-08-25 | 2024-02-29 | LifeEDIT Therapeutics, Inc. | Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing |
| WO2024095245A2 (en) | 2022-11-04 | 2024-05-10 | LifeEDIT Therapeutics, Inc. | Evolved adenine deaminases and rna-guided nuclease fusion proteins with internal insertion sites and methods of use |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4196265A (en) | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5380831A (en) | 1986-04-04 | 1995-01-10 | Mycogen Plant Science, Inc. | Synthetic insecticidal crystal protein gene |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5569597A (en) | 1985-05-13 | 1996-10-29 | Ciba Geigy Corp. | Methods of inserting viral DNA into plant material |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4853331A (en) | 1985-08-16 | 1989-08-01 | Mycogen Corporation | Cloning and expression of Bacillus thuringiensis toxin gene toxic to beetles of the order Coleoptera |
| US5268463A (en) | 1986-11-11 | 1993-12-07 | Jefferson Richard A | Plant promoter α-glucuronidase gene construct |
| US5608142A (en) | 1986-12-03 | 1997-03-04 | Agracetus, Inc. | Insecticidal cotton plants |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5039523A (en) | 1988-10-27 | 1991-08-13 | Mycogen Corporation | Novel Bacillus thuringiensis isolate denoted B.t. PS81F, active against lepidopteran pests, and a gene encoding a lepidopteran-active toxin |
| WO1990011361A1 (en) | 1989-03-17 | 1990-10-04 | E.I. Du Pont De Nemours And Company | External regulation of gene expression |
| EP0452269B1 (en) | 1990-04-12 | 2002-10-09 | Syngenta Participations AG | Tissue-preferential promoters |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5498830A (en) | 1990-06-18 | 1996-03-12 | Monsanto Company | Decreased oil content in plant seeds |
| CA2051562C (en) | 1990-10-12 | 2003-12-02 | Jewel M. Payne | Bacillus thuringiensis isolates active against dipteran pests |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5399680A (en) | 1991-05-22 | 1995-03-21 | The Salk Institute For Biological Studies | Rice chitinase promoter |
| EP0600993B1 (en) | 1991-08-27 | 1999-11-10 | Novartis AG | Proteins with insecticidal properties against homopteran insects and their use in plant protection |
| TW261517B (es) | 1991-11-29 | 1995-11-01 | Mitsubishi Shozi Kk | |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5789156A (en) | 1993-06-14 | 1998-08-04 | Basf Ag | Tetracycline-regulated transcriptional inhibitors |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5608144A (en) | 1994-08-12 | 1997-03-04 | Dna Plant Technology Corp. | Plant group 2 promoters and uses thereof |
| US5659026A (en) | 1995-03-24 | 1997-08-19 | Pioneer Hi-Bred International | ALS3 promoter |
| US6072050A (en) | 1996-06-11 | 2000-06-06 | Pioneer Hi-Bred International, Inc. | Synthetic promoters |
| ATE336580T1 (de) | 1998-02-26 | 2006-09-15 | Pioneer Hi Bred Int | Mais met-1 promoter |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| CA2371442A1 (en) | 1999-05-04 | 2000-11-09 | Monsanto Technology Llc | Coleopteran-toxic polypeptide compositions and insect-resistant transgenic plants |
| AU7491600A (en) | 1999-09-15 | 2001-04-17 | Monsanto Technology Llc | Lepidopteran-active bacillus thuringiensis delta-endotoxin compositions and methods of use |
| US20050183161A1 (en) | 2003-10-14 | 2005-08-18 | Athenix Corporation | AXMI-010, a delta-endotoxin gene and methods for its use |
| US7629504B2 (en) | 2003-12-22 | 2009-12-08 | Pioneer Hi-Bred International, Inc. | Bacillus thuringiensis cry9 nucleic acids |
| WO2007147029A2 (en) | 2006-06-14 | 2007-12-21 | Athenix Corporation | Axmi-031, axmi-039, axmi-040 and axmi-049, a family of delta-endotoxin genes and methods for their use |
| WO2011002992A1 (en) | 2009-07-02 | 2011-01-06 | Athenix Corp. | Axmi-205 pesticidal gene and methods for its use |
| WO2011084324A2 (en) | 2009-12-21 | 2011-07-14 | Pioneer Hi-Bred International, Inc. | Novel bacillus thuringiensis gene with lepidopteran activity |
| CA2807375A1 (en) | 2010-08-19 | 2012-02-23 | Pioneer Hi-Bred International, Inc. | Novel bacillus thuringiensis gene with lepidopteran activity |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| DE202013012242U1 (de) | 2012-05-25 | 2016-02-02 | Emmanuelle Charpentier | Zusammensetzungen für die durch RNA gesteuerte Modifikation einer Ziel-DNA und für die durch RNA gesteuerte Modulation der Transkription |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2016033298A1 (en) | 2014-08-28 | 2016-03-03 | North Carolina State University | Novel cas9 proteins and guiding features for dna targeting and genome editing |
| EP3858990A1 (en) | 2015-03-03 | 2021-08-04 | The General Hospital Corporation | Engineered crispr-cas9 nucleases with altered pam specificity |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| CN111163799A (zh) | 2017-07-28 | 2020-05-15 | 扬森疫苗与预防公司 | 用于异源repRNA免疫接种的方法和组合物 |
| KR20210089629A (ko) | 2018-06-05 | 2021-07-16 | 라이프에디트 테라퓨틱스, 인크. | Rna-가이드된 뉴클레아제 및 그의 활성 단편 및 변이체 및 사용 방법 |
| ES2970169T3 (es) | 2018-12-27 | 2024-05-27 | Lifeedit Therapeutics Inc | Polipéptidos útiles para edición génica y métodos de uso |
| EP4004563B1 (en) | 2019-07-29 | 2024-02-28 | Waters Technologies Corporation | Method of loading samples into a sample manager of a chromatography system |
| KR20220062289A (ko) | 2019-08-12 | 2022-05-16 | 라이프에디트 테라퓨틱스, 인크. | Rna-가이드된 뉴클레아제 및 그의 활성 단편 및 변이체 및 사용 방법 |
| TW202208626A (zh) | 2020-04-24 | 2022-03-01 | 美商生命編輯公司 | Rna引導核酸酶及其活性片段與變體，以及使用方法 |
| AU2021310363A1 (en) * | 2020-07-15 | 2023-03-16 | LifeEDIT Therapeutics, Inc. | Uracil stabilizing proteins and active fragments and variants thereof and methods of use |
-
2022
- 2022-03-22 EP EP22716628.7A patent/EP4314266A1/en active Pending
- 2022-03-22 AU AU2022242754A patent/AU2022242754A1/en active Pending
- 2022-03-22 WO PCT/US2022/021271 patent/WO2022204093A1/en active Application Filing
- 2022-03-22 JP JP2023558569A patent/JP2024511131A/ja active Pending
- 2022-03-22 AR ARP220100668A patent/AR125191A1/es unknown
- 2022-03-22 TW TW111110606A patent/TW202300649A/zh unknown
- 2022-03-22 CN CN202280031917.0A patent/CN117295817A/zh active Pending
- 2022-03-22 CA CA3173950A patent/CA3173950A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022242754A9 (en) | 2023-11-16 |
| CN117295817A (zh) | 2023-12-26 |
| EP4314266A1 (en) | 2024-02-07 |
| CA3173950A1 (en) | 2022-09-22 |
| TW202300649A (zh) | 2023-01-01 |
| AU2022242754A1 (en) | 2023-11-02 |
| JP2024511131A (ja) | 2024-03-12 |
| WO2022204093A1 (en) | 2022-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125191A1 (es) | Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso | |
| ES2525677T3 (es) | Celulasas, genes que las codifican y usos de las mismas | |
| BR112021012665A2 (pt) | Polipeptídeos úteis para edição de genes e métodos de uso | |
| WO2022056254A3 (en) | Dna modifying enzymes and active fragments and variants thereof and methods of use | |
| ATE417927T1 (de) | Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme | |
| JPS59501096A (ja) | 構造遺伝子の製造および発現 | |
| AR062019A1 (es) | Gen de bacillus thuringiensis con actividad contra lepidopteros | |
| KR20240055073A (ko) | 클래스 ii, v형 crispr 시스템 | |
| ATE498013T1 (de) | Für zellzyklusproteine kodierende nukleinsäure und deren verwendung | |
| JP2022529329A (ja) | 人工的に構築されたｒｎａ編集酵素による部位特異的ｒｎａ編集および関連使用 | |
| ATE288488T1 (de) | Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen | |
| AR123483A1 (es) | Enzimas modificadoras de adn y fragmentos activos y variantes de las mismas y métodos de uso | |
| US20210187102A1 (en) | Method of obtaining a polyepitopic protein and polyepitopic dna vector | |
| US20230203462A1 (en) | Modified endonucleases and related methods | |
| AR124216A1 (es) | Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen | |
| DE50014875D1 (de) | Verfahren zum herstellen eines rekombinanten proteins | |
| JPWO2020181102A5 (es) | ||
| AR119634A1 (es) | Nucleasas guiadas por arn y sus fragmentos activos y variantes y métodos de uso | |
| Van Den Hondel et al. | Regulation of gene activity in bacteriophage M13 DNA: Coupled transcription and translation of purified genes and gene-fragments | |
| WO2023155901A1 (en) | Mutant cytidine deaminases with improved editing precision | |
| KR102617593B1 (ko) | 바이러스 뉴클레오캡시드를 이용한 목적 단백질 발현 플랫폼 | |
| JP7125727B1 (ja) | 核酸配列改変用組成物および核酸配列の標的部位を改変する方法 | |
| JPWO2021217002A5 (es) | ||
| WO2023109849A1 (en) | Dna polymerase-mediated genome editing | |
| EP0924295A3 (en) | DNA encoding neospora dihydrofolate reductase-thymidylate synthase |